Giuseppe Cuttone

Dr. Giuseppe Cuttone

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Luigi La ViaLuigi La Via
Luigi La Via
Antonino ManiaciAntonino Maniaci
Antonino Maniaci
MLMario Lentini
Mario Lentini
GCGiuseppe Cuttone
Giuseppe Cuttone
SRSalvatore Ronsivalle
Salvatore Ronsivalle
Andrea MarinoAndrea Marino
Andrea Marino
This narrative review synthesizes our current understanding of sepsis and septic shock burden in intensive care units (ICUs) worldwide. Based on a comprehensive but non-systematic literature search from 2000 to 2025, this review synthesizes our current understanding across eight key domains: epidemiology, pathophysiology, diagnostics, management strategies, long-term outcomes, disparities, and future directions. The global burden of sepsis, especially in the developed and developing world, is great: over 48 million cases per year, with mortality rates at the ICU level in the range of 30 to 50%, depending on geography and resources. The pathophysiological progression from an initial hyper-inflammatory state to immune paralysis underlies organ failure and complicates therapeutic targeting. Diagnostic approaches, including clinical scoring systems, biomarkers (e.g., procalcitonin, MR-proADM), and emerging AI tools, offer improved early detection but face challenges in reliability and accessibility. Management in the ICU remains anchored in timely antimicrobial administration, hemodynamic stabilization with balanced fluids and vasopressors, source control, and organ support, including lung-protective ventilation and kidney replacement therapy. Novel adjuncts, such as immunomodulators and extracorporeal therapies, show promise but demand further validation. Importantly, survivors face significant long-term sequelae—post-intensive care syndrome (PICS)—encompassing physical, cognitive, and psychological impairments, which require structured rehabilitation and follow-up. The future of sepsis care lies in integrating precision medicine—through molecular diagnostics, individualized immunotherapy, and AI-supported monitoring—with scalable, equitable implementation strategies that bridge the gap between high- and low-income settings. Addressing disparities and expanding rehabilitation services are essential to improving survival and long-term quality of life in sepsis survivors.

1 January 2024 in Therapeutic Advances in Pulmonary and Critical Care Medicine
Verified
Journal Article
Open access
GMGiovanni Misseri
Giovanni Misseri
MPMatteo Piattoli
Matteo Piattoli
GCGiuseppe Cuttone
Giuseppe Cuttone
CGCesare Gregoretti
Cesare Gregoretti
EBElena Giovanna Bignami
Elena Giovanna Bignami
With the large volume of data coming from implemented technologies and monitoring systems, intensive care units (ICUs) represent a key area for artificial intelligence (AI) application. Despite the last decade has been marked by studies focused on the use of AI in medicine, its application in mechanical ventilation management is still limited. Optimizing mechanical ventilation is a complex and high-stake intervention, which requires a deep understanding of respiratory pathophysiology. Therefore, this complex task might be supported by AI and machine learning. Most of the studies already published involve the use of AI to predict outcomes for mechanically ventilated patients, including the need for intubation, the respiratory complications, and the weaning readiness and success. In conclusion, the application of AI for the management of mechanical ventilation is still at an early stage and requires a cautious and much less enthusiastic approach. Future research should be focused on AI progressive introduction in the everyday management of mechanically ventilated patients, with the aim to explore the great potentiality of this tool.

Verified
Journal Article
Open access
PDF file
NSNicola Sinatra
Nicola Sinatra
Antonino ManiaciAntonino Maniaci
Antonino Maniaci
GCGiuseppe Cuttone
Giuseppe Cuttone
TTTarek Senussi Testa
Tarek Senussi Testa
STSimona Tutino
Simona Tutino
Luigi La ViaLuigi La Via
Luigi La Via
Critically ill patients receiving continuous renal replacement therapy (CRRT) face distinct nutritional challenges requiring specialized parenteral nutrition (PN) strategies. This review synthesizes current evidence with clinical expertise to provide a comprehensive nutritional framework for this population. Key findings reveal that CRRT significantly impacts nutrient homeostasis through daily losses of amino acids (14–22 g), water-soluble vitamins, and trace elements via the extracorporeal circuit. Results from observational studies demonstrate that higher protein targets (1.8–2.5 g/kg/day) are necessary to achieve positive nitrogen balance, while energy prescriptions must subtract “hidden” calories from citrate anticoagulation (3–4 kcal/mmol) and propofol (1.1 kcal/mL). Clinical outcome data, though primarily observational, indicate that achieving nutritional adequacy correlates with reduced ICU stays (average reduction 2.1–3.4 days), shorter mechanical ventilation duration, and improved functional recovery. Evidence supports that early PN prescription when indicated, coupled with systematic consideration of therapy modality, extracorporeal losses, oral intake capacity, and mobilization status, optimizes nutritional support. We conclude that successful implementation requires: (1) dynamic adjustment based on CRRT parameters, (2) integration with enteral nutrition when feasible, (3) regular metabolic monitoring, (4) multidisciplinary collaboration, and (5) structured protocols. Future research using point-of-care analysis and AI-driven support systems is needed to establish evidence-based guidelines in this specialized population.

19 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
GCGiuseppe Cuttone
Giuseppe Cuttone
GGGiulio Geraci
Giulio Geraci
Luigi La ViaLuigi La Via
Luigi La Via
Massimiliano SorbelloMassimiliano Sorbello
Massimiliano Sorbello
FPFederico Pappalardo
Federico Pappalardo
CCCaterina Carollo
Caterina Carollo
The renal resistive index (RRI), a Doppler ultrasound-derived parameter measuring renal vascular resistance, has emerged as a promising non-invasive tool to evaluate renal hemodynamics in critically ill patients, particularly those with acute respiratory distress syndrome (ARDS) and heart failure (HF). This narrative review examines the current evidence for RRI measurement in these conditions, exploring its physiological bases, methodology, clinical applications, and limitations. In ARDS, RRI reflects the complex interactions between positive pressure ventilation, hypoxemia, and systemic inflammation, showing a role in predicting acute kidney injury and monitoring response to interventions. In HF, RRI is able to assess venous congestion and cardiorenal interactions and can also serve as a prognostic indicator. Many studies have shown RRI’s superiority or complementarity to traditional biomarkers in predicting renal dysfunction, although its interpretation requires consideration of multiple patient-related factors. Key challenges include operator dependency, lack of standardization, and complex interpretation in multi-organ dysfunction. Future research should focus on measurement standardization, development of automated techniques, investigation of novel applications like intraparenchymal renal resistive index variation, and validation of RRI-guided management strategies. Despite its limitations, RRI represents a valuable tool that offers bedside and real-time insights into renal hemodynamics and potential guidance for therapeutic interventions. Further research is needed to fully clarify its clinical potential and address current limitations, particularly in critical care settings involving multiple organ dysfunction.

4 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FVFrancesco Vetrone
Francesco Vetrone
FSFrancesco Saglietti
Francesco Saglietti
AGAndrea Galimberti
Andrea Galimberti
PAPezzi Angelo
Pezzi Angelo
Michele UmbrelloMichele Umbrello
Michele Umbrello
AGAlessandro Girombelli
Alessandro Girombelli
Background: Optimal pain control with limited muscle weakness after total hip arthroplasty (THA) is paramount for a swift initiation of physical therapy and ambulation, thus expediting hospital discharge. FICB (Fascia Iliaca Compartment Block) has been recommended because it offers pain control with a low risk of motor block. PENG (Pericapsular Nerve Group) block with LFCN (Lateral Femoral Cutaneous Nerve) has been proposed as an alternative that offers comparable pain control with a lower risk of motor block; however, evidence is limited. We aimed to investigate the degree of muscle weakness and pain control with PENG + LFCN. Methods: Patients undergoing elective THA from November 2022 to October 2023 have been retrospectively analyzed. The degree of quadriceps femoris muscle paresis was assessed with the MRC scale at 6 h postoperatively. Secondary outcomes: NRS score at 6, 12, and 24 h, total opioid consumption, and time to first rescue opioid. Results: In total, 80 patients were included in the study, 57 received PENG + LFCN, and the remaining 23 received FICB. PENG + LCFN resulted in a higher MRC at 6 h (4 [4; 5] vs. 3 [2; 4] p = 0.0001) and better pain control (mean difference [95% CI] at 6 h, 0.93 [0.14; 1.72], at 12 h, 0.47 [−0.49; 1.43], and at 24 h, 0.39 [0.25; 1.2], p = 0.0006). Less PRN opioids were requested in the PENG + LFCN vs. FICB groups (7.5 [0; 15] MME vs. 60 [40; 80], p = 0.001). Conclusions: PENG + LFCN was associated with less muscle weakness, better pain control, and less rescue opioids in patients undergoing elective THA. A larger prospective study is needed to confirm this finding.

9 June 2025 in Diseases
Verified
Journal Article
Open access
PDF file
GGGiulio Geraci
Giulio Geraci
Pietro FerraraPietro Ferrara
Pietro Ferrara
Luigi La ViaLuigi La Via
Luigi La Via
ASAlessandra Sorce
Alessandra Sorce
VCVincenzo Calabrese
Vincenzo Calabrese
CCCaterina Carollo
Caterina Carollo
Duplex-Doppler ultrasonography has become an essential tool in the diagnosis and management of kidney diseases, allowing clinicians to assess renal hemodynamics, detect vascular abnormalities, and monitor disease progression. Among the various Doppler-derived parameters, the renal resistive index (RRI) has gained particular attention both as a diagnostic tool and a prognostic marker in nephrology. Traditionally considered an indicator of parenchymal perfusion, recent evidence highlights its strong association with systemic hemodynamic factors, particularly arterial stiffness, positioning RRI as a valuable tool for evaluating patients with systemic vascular impairment, such as hypertension, diabetes mellitus, and atherosclerosis. RRI has been strongly linked to vascular damage, which in turn is influenced by inflammation and endothelial dysfunction, making it a reliable marker of cardiovascular damage and a potential predictor of cardiovascular risk. Furthermore, emerging studies suggest that RRI could serve as a dynamic parameter to monitor vascular changes induced by therapeutic interventions. This narrative review summarizes the classic and evolving applications of RRI, from its origin as a renal hemodynamic marker to its emerging role as a systemic vascular biomarker with diagnostic and prognostic significance in cardiovascular and metabolic diseases.